சன்ஸ்டோன் வாழ்க்கை அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

(0) Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women s health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo s therapeutic concept. The company is now planning the Phase 2 program including endometriosis patients in the US. The now completed Phase 1 program delivered an initial body of tolerability, safety and pharmacokinetic data. For chronic endometriosis treatment, tolerability and a lack of systemic estrogen deficiency-related side effects are of the utmost importance as we see current therapies struggling to be widely adopted due to their side effect profiles. A local effect on the target tissue with our intracrinolog

Kostenloser wertpapierhandelForendo pharmaCaroline rufoRisto lammintaustaKarolinska developmentNovartis venture fundEnovo seedsVesalius biocapitalSunstone life scienceDougall advisorsகரோலின் ரூஃபோநோவர்த்திச் துணிகர நிதிநோவோ விதைகள்சன்ஸ்டோன் வாழ்க்கை அறிவியல்

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

Forendo pharmaCaroline rufoRisto lammintaustaKarolinska developmentNovartis venture fundEnovo seedsVesalius biocapitalSunstone life scienceகரோலின் ரூஃபோநோவர்த்திச் துணிகர நிதிநோவோ விதைகள்சன்ஸ்டோன் வாழ்க்கை அறிவியல்

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

(2) COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners 1, PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital, with the participation of existing investors Novo Seeds, Lundbeckfonden Emerge and Sunstone Life Science Ventures. Additionally, Dr. Priyanka Belawat of HBM Partners, Jack B. Nielsen of Vivo Capital and Vanessa Malier of Kurma Partners will join IO Biotech s board of directors as part of the closing of the financing.

Jennifer williamsKostenloser wertpapierhandelPriyanka belawatChristian ellingMai britt zoccaJackb nielsenVanessa malierDrug administrationVirtual congressEuropean society for medical oncologyHealth sciencesCook williams communications incVivo capitalKurma partnersAvoro capitalSamsara biocapital

Novo Seeds Portfolio Company, IO Biotech, Completes Oversubscribed EUR 127M Series B Financing to Accelerate Clinical Programs in Oncology

Novo Seeds Portfolio Company, IO Biotech, Completes Oversubscribed EUR 127M Series B Financing to Accelerate Clinical Programs in Oncology - IO Biotech to accelerate the development of novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology - Novo Seeds created and launched IO Biotech with first seed investment in 2015 - Participated in further financing alongside a strong syndicate of investors News provided by Share this article Share this article COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ Novo Seeds, the early-stage investment and company creation team of Novo Holdings, announced today that its portfolio company, IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, has raised EUR 127 million in Series B financing.

Emmanuelle coutanceauMai britt zoccaDrug administrationVirtual congressEuropean society for medical oncologyHealth sciencesNovo holdingsEnovo seedsBoard memberFor novo seedsChief executive officerLundbeckfonden emergeSunstone life scienceVivo capitalKurma partnersAvoro capital